Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 7, 2006; 12(29): 4721-4726
Published online Aug 7, 2006. doi: 10.3748/wjg.v12.i29.4721
Published online Aug 7, 2006. doi: 10.3748/wjg.v12.i29.4721
Table 1 Demographic profile of patients with chronic HCV infection and healthy controls
Patients(n = 252) | Patients(Only genotype 3)(n = 187) | Healthycontrols(n = 408) | |
Age (yr) | |||
Mean ± SD | 40 ± 14 | 40 ± 14 | 33 ± 7 |
Male: Female | 164:88 | 118:69 | 297:111 |
ALT (IU/L) | |||
Mean | 112.3 ± 68.4 | 116 ± 70.1 | 29 ± 2 |
Range | (32-330) | (32-330) | |
S. Albumin (g/L) | 36 ± 4 | 34 ± 5 | 40 ± 3 |
HCV genotype (n = 209) | |||
I | 17 (8.1%) | - | |
II | 1 (0.5%) | ||
III | 187 (89.4%) | - | |
IV | 4 (1.5%) | - | |
Liver Biopsy | |||
Fibrosis score | 2 ± 1 | 2 ± 1.2 | - |
HAI | 5.5 ± 2.4 | 5.6 ± 2.5 | - |
Mode of Acquisition of HCV | |||
Blood transfusion | 86 | - | |
Needle stick injury | 54 | - | |
Intravenous drug use | 10 | - | |
Medical procedure | 45 | - | |
Unclear | 57 |
Table 2 Allele frequency of CCR5 variants in chronic HCV patients and healthy controls
CCR5 | HCV Patients(n = 252) | Healthy Controls(n = 408) | P value |
Wt/wt | 247 (98%) | 405 (99.3%) | 0.07 |
Δ32mt carrier | 5 (1.9%) | 3 (0.7%) | 0.3 |
Wt/Δ32 | 3 (1.2%) | 3 (0.7%) | 0.2 |
aΔ32mt/Δ32mt | 2 (0.7%) | - | 0.1 |
Table 3 Correlation of Immune Gene Polymorphism and histological severity of HCV Related Liver Disease in Univariate analysis
Liver histology | CCR5-Genotype | P | ||
wt/wt | wt/Δ32 | Δ32/Δ32 | ||
Fibrosis | ||||
≤ 2 (n = 162) | 154 (98%) | 1 (0.6%) | 2 (1.2%) | |
> 2 (n = 90) | 88 (97.8%) | 2 (1.2%) | 0 | NS |
HAI | ||||
≤ 5 (n = 162) | 170 (98.3%) | 1 (0.6%) | 2 (1.2%) | |
> 5 (n = 90) | 77 (97.5%) | 2 (2.5&) | 0 | NS |
Table 4 Response patterns in HCV patients genotyped for CCR5
Response | CCR5-Genotype | P | |||
wt/wt | wt/Δ32 | Δ32/Δ32 | |||
IFN+ Riba/ Peg IFN+ Rib | Responders | 86 | 1 | - | NS |
Non-responders | 34 | 1 | - | NS | |
Relapsers | 7 | - | - | NS |
Table 5 Analysis of published data in chronic HCV patients genotyped for CCR5Δ32 mutation
Authors | Susceptibility | Histological Severity | Response to therapy | Genotype | Patients studied (n) |
Ahlensteil G et al[27,28] | Yes | Not mentioned | Lower ETR1 | Genotype 1 Genotype 2 | 59 3 |
Genotype 3 | 9 | ||||
Genotype 4 | 3 | ||||
Undetermined | 4 | ||||
Glas J et al[29] | No | Not mentioned | No | Genotype 1/4 | 37 |
Genotype 2/3 | 25 | ||||
Goulding C et al[26] | 2Spontaneous viral clearance | 2Lower hepatic inflammation | Not mentioned | Genotype 1b | 283 |
Hellier et al[13] | No | Decreased portal inflammation | No | Stratification not mentioned | |
Konishi et al[30] | No | No | No | Serotype 1 | 53 |
Serotype 2 | 48 | ||||
Serotype 1 + 2 | 4 | ||||
Mascheretti et al[31] | No | No | No | Genotype 1 | 358 |
Genotype 2 | 14 | ||||
Genotype 3 | 79 | ||||
Genotype 4 | 14 | ||||
Promrat et al[12] | No | No | No | Genotype 1 | 243 |
Genotype 2 | 34 | ||||
Genotype 3 | 16 | ||||
Genotype 4 | 3 | ||||
Genotype 5 | 1 | ||||
Undetermined | 42 | ||||
Wald et al[32] | No | Significantly reduced | Not mentioned | Genotype 1 | 5 |
Genotype 2 | 2 | ||||
Genotype 3 | 9 | ||||
Undetermined | 31 | ||||
Wasmuth et al[33] | No | No | No | Genotype 1 | 213 |
Non-Genotype 1 | 117 | ||||
Woitas et al[11] | Yes | Not mentioned | Not mentioned | Genotype 1 | 95 |
Genotype 2 | 16 | ||||
Genotype 3 | 10 | ||||
Genotype 4 | 6 | ||||
Multiple genotype | 5 | ||||
Undetermined | 2 | ||||
Present study Goyal et al | No | No | No | Genotype 1 | 16 |
Genotype 2 | 1 | ||||
Genotype 3 | 161 | ||||
Genotype 4 | 4 | ||||
Undetermined | 70 |
- Citation: Goyal A, Suneetha P, Kumar G, Shukla DK, Arora N, Sarin SK. CCR5Δ32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12(29): 4721-4726
- URL: https://www.wjgnet.com/1007-9327/full/v12/i29/4721.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i29.4721